Bioactive magnetic near Infra-Red fluorescent core-shell iron oxide/human serum albumin nanoparticles for controlled release of growth factors for augmentation of human mesenchymal stem cell growth and differentiation

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Levy, Itay ^a   Sher, Ifat ^b   Corem Salkmon, Enav ^a   Ziv Polat, Ofra ^a   Meir, Amilia ^c   Treves, Avraham J ^c   Nagler, Arnon ^c   Kalter Leibovici, Ofra ^b   Margel, Shlomo ^a   Rotenstreich, Ygal ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

BM MSCs; FGF2; IO HSA NPs

Indexed keywords

BIOACTIVITY; BODY FLUIDS; BONE; CELL PROLIFERATION; CELLS; CYTOLOGY; ENDOTHELIAL CELLS; ENZYME INHIBITION; FLOWCHARTING; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; IRON OXIDES; LIGHT SCATTERING; MEDICAL APPLICATIONS; MOLECULAR BIOLOGY; NANOMAGNETICS; NANOPARTICLES; NEURONS; PROTEINS; SHELLS (STRUCTURES); STEM CELLS; TISSUE CULTURE; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET VISIBLE SPECTROSCOPY;

BM-MSCS; FGF2; FIBROBLAST GROWTH FACTOR 2; GLIAL FIBRILLARY ACIDIC PROTEINS; HUMAN BONE MARROW MESENCHYMAL STEM CELLS; HUMAN MESENCHYMAL STEM CELLS; IO/HSA NPS; MICROTUBULE ASSOCIATED PROTEIN;

CELL CULTURE;

FIBROBLAST GROWTH FACTOR 2; GLIAL FIBRILLARY ACIDIC PROTEIN; GROWTH FACTOR; HUMAN SERUM ALBUMIN; IRON OXIDE; MAGNETIC NANOPARTICLE; MICROTUBULE ASSOCIATED PROTEIN 2; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE; SERUM ALBUMIN;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CONJUGATION; CONTROLLED STUDY; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HISTOCHEMISTRY; HUMAN; HUMAN CELL; INTERNALIZATION; LIGHT SCATTERING; MESENCHYMAL STEM CELL; OSTEOBLAST; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; ADIPOGENESIS; BLEACHING; BONE DEVELOPMENT; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG STABILITY; FLUORESCENCE; MESENCHYMAL STROMA CELL; PARTICLE SIZE; SPECTROFLUOROMETRY;

ADIPOGENESIS; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG STABILITY; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTOR 2; FLUORESCENCE; HUMANS; MAGNETITE NANOPARTICLES; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; PARTICLE SIZE; PHOTOBLEACHING; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE;

EID: 84930197316     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0090-8     Document Type: Article

References (67)

1. Hergt R, Hiergeist R, Hilger I, Kaiser W, Lapatnikov Y, Margel S, et al. Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia. J Magn Magn Mater. 2004;270:345-57.
2. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008;2:889-96.
3. Rogers WJ, Meyer CH, Kramer CM. Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract Cardiovasc Med. 2006;3:554-62.
4. Pankhurst QA, Connolly J, Jones S, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36:R167-81.
5. Qiao R, Yang C, Gao M. Superparamagnetic iron oxide nanoparticles: from preparations to in vivo MRI applications. J Mater Chem. 2009;19:6274-93.
6. Park YI, Piao Y, Lee N, Yoo B, Kim BH, Choi SH, et al. Transformation of hydrophobic iron oxide nanoparticles to hydrophilic and biocompatible maghemite nanocrystals for use as highly efficient MRI contrast agent. J Mater Chem. 2011;21:11472-7.
7. Jin X, Chen K, Huang J, Lee S, Wang J, Gao J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31:3016-22.
8. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2:22-32.
9. Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 2007;129:12739-45.
10. Altinoğlu EI, Adair JH. Near infrared imaging with nanoparticles. WIREs Nanomed Nanobiotechnol. 2010;2:461-77.
11. Kinsella JM, Jimenez RE, Karmali PP, Rush AM, Kotamraju VR, Gianneschi NC, et al. X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Ed Engl. 2011;50:12308-11.
12. He X, Wang K, Cheng Z. In vivo near-infrared fluorescence imaging of cancer with nanoparticle based probes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2:349-66.
13. Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S, et al. Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine. 2011;6:1595-602.
14. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Controlled Release. 2008;132:171-83.
15. Galperin A, Margel S. Synthesis and characterization of radiopaque magnetic core shell nanoparticles for X-ray imaging applications. J Biomed Mater Res B Appl Biomater. 2007;83:490-8.
16. Boguslavsky Y, Margel S. Synthesis and characterization of poly (divinylbenzene)-coated magnetic iron oxide nanoparticles as precursor for the formation of Air-stable carbon-coated iron crystalline nanoparticles. J Colloid Interface Sci. 2008;317:101-14.
17. MacDonald K, Murrell WG, Bartlett P, Bushell GR, Mackay Sim A. FGF2 promotes neuronal differentiation in explant cultures of adult and embryonic mouse olfactory epithelium. J Neurosci Res. 1996;44:27-39.
18. Huang Y-C, Huang Y-Y. Tissue engineering for nerve repair. Biomed Eng Appl Basis Commun. 2006;18:100-10.
19. Wu Y, Cai W, Chen X. Near-infrared fluorescence imaging of tumor integrin Avβ3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol. 2006;8:226-36.
20. Zhang S, Uludağ H. Nanoparticulate systems for growth factor delivery. Pharm Res. 2009;26:1561-80.
21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7.
22. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 1999;96:10711-6.
23. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377-84.
24. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41-9.
25. Mezey E, Key S, Vogelsang G, Szalayova I, Lange GD, Crain B. Transplanted bone marrow generates New neurons in human brains. Proc Natl Acad Sci U S A. 2003;100:1364-9.
26. Arien-Zakay H, Lazarovici P, Nagler A. Tissue regeneration potential in human umbilical cord. Best Pract Res Clin Haematol. 2010;23:291-303.
27. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101:3722-9.
28. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-43.
29. Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther. 2009;9:1487-97.
30. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225-38.
31. Michael M, Shimoni A, Nagler A. Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease. Isr Med Assoc J. 2013;15:44-50.
32. Petite H, Viateau V, Bensaid W, Meunier A, de Pollak C, Bourguignon M, et al. Tissue-engineered bone regeneration. Nat Biotechnol. 2000;18:959-63.
33. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells. 2007;25:2896-902.
34. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-7.
35. Tzameret A, Sher I, Belkin M, Treves AJ, Meir A, Nagler A, et al. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a Rat model of retinal dystrophy. Exp Eye Res. 2014;118:135-44.
36. Xiong N, Yang H, Liu L, Xiong J, Zhang Z, Zhang X, et al. bFGF promotes the differentiation and effectiveness of human bone marrow mesenchymal stem cells in a rotenone model for Parkinson's disease. Environ Toxicol Pharmacol. 2013;36:411-22.
37. Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae J. Intracerebral transplantation of bone marrow derived mesenchymal stem cells reduces amyloid beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. Stem Cells. 2010;28:329-43.
38. Yu J, Yin S, Zhang W, Gao F, Liu Y, Chen Z, et al. Hypoxia preconditioned bone marrow mesenchymal stem cells promoted liver regeneration in a Rat massive hepatectomy model. Stem Cell Res Ther. 2013;4:83.
39. Zhao Y, Xu A, Xu Q, Zhao W, Li D, Fang X, et al. Bone marrow mesenchymal stem cell transplantation for treatment of emphysemic rats. Int J Clin Exp Med. 2014;7:968-72.
40. Chen SL, Fang WW, Qian J, Ye F, Liu YH, Shan SJ, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl). 2004;117:1443-8.
41. Dabiri G, Heiner D, Falanga V. The emerging use of bone marrow-derived mesenchymal stem cells in the treatment of human chronic wounds. Expert Opin Emerg Drugs. 2013;18:405-19.
42. Gopal K, Amirhamed HA, Kamarul T. Advances of human bone marrow-derived mesenchymal stem cells in the treatment of cartilage defects: a systematic review. Exp Biol Med (Maywood). 2014;239:663-9.
43. Pal R, Venkataramana NK, Bansal A, Balaraju S, Jan M, Chandra R, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009;11:897-911.
44. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206-13.
45. Bianco Martinez AM, de Oliveira GC, dos Santos RB, Teixeira Oliveira J, Martins Almeida F. Neurotrauma and mesenchymal stem cells treatment: from experimental studies to clinical trials. World J Stem Cells. 2014;6:179-94.
46. ClinicalTrials.gov, https://clinicaltrials.gov/ . Accessed 2014.
47. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-7.
48. DiGirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol. 1999;107:275-81.
49. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, Daniels D, et al. Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation. 2007;116:I38-45.
50. Auletta JJ, Zale EA, Welter JF, Solchaga LA. Fibroblast growth factor-2 enhances expansion of human bone marrow-derived mesenchymal stromal cells without diminishing their immunosuppressive potential. Stem Cells Int. 2011;2011:235176.
51. Bianchi G, Banfi A, Mastrogiacomo M, Notaro R, Luzzatto L, Cancedda R, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res. 2003;287:98-105.
52. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci U S A. 1993;90:1513-7.
53. Whalen GF, Shing Y, Folkman J. The fate of intravenously administered bFGF and the effect of heparin. Growth Factors. 1989;1:157-64.
54. Skaat H, Ziv-Polat O, Shahar A, Last D, Mardor Y, Margel S. Magnetic scaffolds enriched with bioactive nanoparticles for tissue engineering. Adv Healthc Mater. 2012;1:168-71.
55. Ziv-Polat O, Topaz M, Brosh T, Margel S. Enhancement of incisional wound healing by thrombin conjugated iron oxide nanoparticles. Biomaterials. 2010;31:741-7.
56. Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, Kinor N, Boguslavsky Y, Margel S, et al. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats. Exp Neurol. 2005;194:97-105.
57. Ziv-Polat O, Skaat H, Shahar A, Margel S. Novel magnetic fibrin hydrogel scaffolds containing thrombin and growth factors conjugated iron oxide nanoparticles for tissue engineering. Int J Nanomedicine. 2012;7:1259-74.
58. Perlstein B, Lublin-Tennenbaum T, Marom I, Margel S. Synthesis and characterization of functionalized magnetic maghemite nanoparticles with fluorescent probe capabilities for biological applications. J Biomed Mater Res BAppl Biomater. 2010;92:353-60.
59. Ahn HJ, Lee WJ, Kwack K, Kwon YD. FGF2 stimulates the proliferation of human mesenchymal stem cells through the transient activation of JNK signaling. FEBS Lett. 2009;583:2922-6.
60. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF 2 enhances the mitotic and chondrogenic potentials of human adult bone marrow derived mesenchymal stem cells. J Cell Physiol. 2005;203:398-409.
61. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24:462-71.
62. Dombrowski C, Helledie T, Ling L, Grunert M, Canning CA, Jones CM, et al. FGFR1 signaling stimulates proliferation of human mesenchymal stem cells by inhibiting the cyclin-dependent kinase inhibitors P21 and P27. Stem Cells. 2013;31:2724-36.
63. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575-602.
64. Swami A, Shi J, Gadde S, Votruba AR, Kolishetti N, Farokhzad OC. Nanoparticles for targeted and temporally controlled drug delivery. In: Nanoparticles for targeted and temporally controlled drug delivery. Multifunctional Nanoparticles for Drug Delivery Applications: Springer, 2012: 9-29
65. Phinney DG. Building a consensus regarding the nature and origin of mesenchymal stem cells. J Cell Biochem. 2002;85:7-12.
66. Margel S, Tennenbaum T, Gura S. Synthesis and characterization of nano and micron sized iron oxide and iron particles for biomedical applications. Lab Tech Biochem Mol Biol. 2007;32:119-62.
67. Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51:2415-8.